These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32334110)

  • 1. In vivo antitumoral effect of 4-nerolidylcatechol (4-NC) in NRAS-mutant human melanoma.
    Alves-Fernandes DK; Oliveira ÉA; Hastreiter AA; Faião-Flores F; Felipe-Silva AS; Turato W; Fock RA; Maria-Engler SS; Barros SBM
    Food Chem Toxicol; 2020 Jul; 141():111371. PubMed ID: 32334110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
    Alves-Fernandes DK; Oliveira ÉA; Faião-Flores F; Alicea-Rebecca G; Weeraratna AT; Smalley KSM; Barros SBM; Maria-Engler SS
    Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
    Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
    [No Abstract]   [Full Text] [Related]  

  • 4. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
    Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
    Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
    Arozarena I; Goicoechea I; Erice O; Ferguson J; Margison GP; Wellbrock C
    Mol Cancer; 2014 Jun; 13():154. PubMed ID: 24941944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
    Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
    PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
    Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
    Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
    Haarberg HE; Paraiso KH; Wood E; Rebecca VW; Sondak VK; Koomen JM; Smalley KS
    Mol Cancer Ther; 2013 Jun; 12(6):901-12. PubMed ID: 23538902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
    Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
    Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis induction by 4-nerolidylcatechol in melanoma cell lines.
    Brohem CA; Sawada TC; Massaro RR; Almeida RL; Rivelli DP; Ropke CD; da Silva VV; de Lima TM; Curi R; Barros SB; Maria-Engler SS
    Toxicol In Vitro; 2009 Feb; 23(1):111-9. PubMed ID: 19059332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of NRAS-mutant melanoma.
    Johnson DB; Puzanov I
    Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRAS mutant melanoma: Towards better therapies.
    Randic T; Kozar I; Margue C; Utikal J; Kreis S
    Cancer Treat Rev; 2021 Sep; 99():102238. PubMed ID: 34098219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
    Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
    Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
    Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
    Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death.
    Brohem CA; Massaro RR; Tiago M; Marinho CE; Jasiulionis MG; de Almeida RL; Rivelli DP; Albuquerque RC; de Oliveira TF; de Melo Loureiro AP; Okada S; Soengas MS; de Moraes Barros SB; Maria-Engler SS
    Pigment Cell Melanoma Res; 2012 May; 25(3):354-69. PubMed ID: 22372875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRAS
    Banik I; Cheng PF; Dooley CM; Travnickova J; Merteroglu M; Dummer R; Patton EE; Busch-Nentwich EM; Levesque MP
    Pigment Cell Melanoma Res; 2021 Mar; 34(2):150-162. PubMed ID: 32910840
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.
    Rinner B; Gandolfi G; Meditz K; Frisch MT; Wagner K; Ciarrocchi A; Torricelli F; Koivuniemi R; Niklander J; Liegl-Atzwanger B; Lohberger B; Heitzer E; Ghaffari-Tabrizi-Wizsy N; Zweytick D; Zalaudek I
    Sci Rep; 2017 May; 7(1):2098. PubMed ID: 28522871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.